Highlights Immuron Limited Nasdaq

Equities

IMRN

US45254U1016

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-10 pm EDT			5-day change	1st Jan Change
2.03 ^USD	-9.78%		+0.50%	+8.27%

Jul. 03	Immuron Files for Mixed-Shelf Offering; Plans to Raise $2M Through At-The-Market Equity Sale	MT
Jul. 02	Immuron Requests Meeting With FDA for Potential Colon Infection Therapy	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing	Jul. 02	CI
Immuron Files Pre-Investigational New Drug Application with FDA for IMM-529	Jul. 01	MT
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	Apr. 09	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	Mar. 07	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Immuron Limited Clinical Trials Update	Dec. 22	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	Dec. 04	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	23-10-18	CI
Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Immuron Limited Receives TGA GMP Clearance	23-08-09	CI
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%	23-08-09	MT
Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study	23-07-25	CI
Immuron Says Ateria Health Introduces Juvia Digestive Formula in Australia	23-07-11	MT
Immuron Limited Approves Proceeding with IMM-529 cGMP Manufacturing and to Proceed with FDA Pre-IND Submission	23-06-22	CI
Immuron Limited Initiates Recruitment of Travelan Clinical Study	23-05-30	CI
PacWest Bancorp, Inflation in Focus Amid Mixed Exchange-Traded Funds, Equity Futures in Premarket Activity	23-05-08	MT
Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation	23-05-08	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic	23-01-24	CI
Immuron Obtains European Patent for Drug Composition to Treat Clostridioides Difficile Associated Disease	23-01-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immuron Limited Nasdaq

Equities

IMRN

US45254U1016

Highlights

Filters